Satsuma Pharmaceuticals Net income (FY, 2018)-7.3 M
Satsuma Pharmaceuticals EBIT (FY, 2018)-7.5 M
Satsuma Pharmaceuticals Cash, 31-Dec-20185.2 M

Satsuma Pharmaceuticals Income Statement

Annual

USDFY, 2017FY, 2018

R&D expense

4.2m6.4m

General and administrative expense

754.0k1.1m

Operating expense total

4.9m7.5m

EBIT

(4.9m)(7.5m)

Interest expense

15.0k90.0k

Interest income

30.0k72.0k

Net Income

(5.2m)(7.3m)

Satsuma Pharmaceuticals Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

1.7m5.2m

Prepaid Expenses

256.0k199.0k

Current Assets

1.9m5.4m

PP&E

70.0k445.0k

Total Assets

2.0m6.4m

Accounts Payable

473.0k327.0k

Short-term debt

291.0k141.0k

Current Liabilities

1.7m2.0m

Long-term debt

4.8m

Total Debt

291.0k5.0m

Total Liabilities

1.9m6.9m

Common Stock

1.0k

Preferred Stock

5.5m11.6m

Additional Paid-in Capital

2.0m2.7m

Retained Earnings

(7.5m)(14.8m)

Total Equity

96.0k(484.0k)

Debt to Equity Ratio

3 x-10.3 x

Debt to Assets Ratio

0.1 x0.8 x

Financial Leverage

20.7 x-13.2 x

Satsuma Pharmaceuticals Cash Flow

Annual

USDFY, 2017FY, 2018

Net Income

(5.2m)(7.3m)

Depreciation and Amortization

10.0k57.0k

Accounts Payable

363.0k(177.0k)

Cash From Operating Activities

(4.3m)(7.0m)

Purchases of PP&E

(58.0k)(402.0k)

Cash From Investing Activities

(58.0k)(402.0k)

Cash From Financing Activities

10.9m

Net Change in Cash

(4.4m)3.5m

Interest Paid

34.0k

Income Taxes Paid

1.0k4.0k

Satsuma Pharmaceuticals Ratios

USDY, 2018

Debt/Equity

-10.3 x

Debt/Assets

0.8 x

Financial Leverage

-13.2 x

Satsuma Pharmaceuticals Operating Metrics

Aug, 2019

Drugs in Development

37

Patents (Foreign)

9

Patents (US)

6